Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben...
Transcript of Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben...
![Page 1: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/1.jpg)
Angelman Syndrome: Research Updates
Ben Philpot, Ph.D. , University of North Carolina
Stormy Chamberlain, Ph.D., University of Connecticut
ASF Research Updates
Stormy J. Chamberlain, PhD
John and Donna Krenicki Professor of Genomics and Personalized Healthcare
Associate Professor of Genetics and Genome Sciences
University of Connecticut, School of Medicine
Chair, Scientific Advisory Committee, Angelman Syndrome Foundation
![Page 2: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/2.jpg)
Our Research Goal
• To improve the lives of individuals with Angelman syndrome
![Page 3: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/3.jpg)
ASF’s research funding philosophy
Studies to better
understand UBE3A
High-risk, high-
reward studies to
find therapeutics
Clinical studies to
understand AS and
improve life
![Page 4: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/4.jpg)
How we fund• Seed funding to generate preliminary data
• Promising studies can then be further funded by NIH, SFARI, pharma
e.g. $200,000 to Dr. Mark Zylka in 2016 for his CRISPR studies resulted in a
$2.8 million grant to him from the NIH in 2019
Peer review
• Any scientist or clinician can submit a grant application to the ASF
• Proposals are reviewed twice a year by the scientific advisory committee
Scientific Advisory Committee (SAC)
• 19 member committee comprised of scientists, clinicians, and parents
• Review grants individually, and then meet by phone to discuss and score
![Page 5: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/5.jpg)
Cell
Nucleus Chromosome
DNA
Gene
http://www.gencodys.eu/
![Page 6: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/6.jpg)
Neurons
(brain cells)
Nucleus Chromosome 15
DNA
UBE3A
http://www.gencodys.eu/
![Page 7: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/7.jpg)
Unlike most chromosomes, mom’s and dad’s copies of
chromosome 15 are different from one another
The chromosome 15q11-q13 region is where
the UBE3A gene is located.
![Page 8: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/8.jpg)
Some genes on chromosome 15q11-q13 are made from
mom’s copy and some are made from dad’s copy
PAT
MAT
MAGEL2
NDN
SNURF-
SNRPN
MKRN3
UBE3A
ATP10A
SNORD116
UBE3A-ATS
IPW
BP1
BP2
PWS-IC
AS-IC B
P3
* DNA methylation determines the difference between mom’s and dad’s chromosomes 15.
![Page 9: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/9.jpg)
MAGEL2
NDN
SNURF-
SNRPN
MKRN3
UBE3A
ATP10A
SNORD116
UBE3A-ATS
IPW
BP1
BP2
PWS-IC
PAT
MAT
When mom’s copy is missing, UBE3A is not made in neurons
AS-IC B
P3
![Page 10: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/10.jpg)
There are four “common” ways to lose mom’s copy of UBE3A
UBE3A
pat. mat.
15q11-q13
Typical Deletion
(~70%)
UBE3A mutation
(~10-15%)
UPD
(~3-5%)Imprinting defect
(~2-5%)
![Page 11: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/11.jpg)
Dr. David Godler, MD
Murdoch Children’s Research Institute,
Australia
• Developed an inexpensive methylation test ideal for use in
newborn screening for AS.
• Partnered funding with Foundation for Prader-Willi Research
and Dup15q Alliance.
ASF co-funded research to develop newborn screening
![Page 12: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/12.jpg)
What does UBE3A do?
![Page 13: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/13.jpg)
How do mutations in UBE3A cause AS?
Dr. Jason Yi, PhD
Washington University, St. Louis
• Catalogue all of the UBE3A mutations that cause AS and
determine how they disable UBE3A protein function.
• Identify areas where mutations have unusually large impact on
UBE3A function.
• Will aid in interpretations of genetic tests for diagnosis of AS.
![Page 14: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/14.jpg)
Dr. Gilles Trave, PhD
European Center of Research
and Biology, Illkirch, France
• Determine the 3D structure of full-length UBE3A with and
without HERC2
• Determine other proteins that interact with UBE3A +/- HERC2
• Important for understanding how UBE3A works with and
without HERC2 to impact brain development
What is the full structure of UBE3A protein?
https://en.wikipedia.org/wiki/UBE3A
![Page 15: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/15.jpg)
Where in the cell is UBE3A?
• Two different “forms” of UBE3A in mouse may be located in
different parts of the cell. Short form is located in the nucleus,
long form is located in the cytoplasm
• Short form accounts for ~80% of total UBE3A protein
Dr. Ype Elgersma, PhD
Erasmus Medical Centre, Rotterdam
![Page 16: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/16.jpg)
Where in the cell is UBE3A?
Dr. Ben Philpot, PhD
University of North
Carolina
• Overall, human UBE3A protein looks similar to that in mouse
• Humans have three different “forms” and their location may
differ from mouse forms.
Dr. Stormy
Chamberlain, PhD
UConn Health
![Page 17: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/17.jpg)
ASF’s research funding philosophy
Studies to better
understand UBE3A
High-risk, high-
reward studies to
find therapeutics
Clinical studies to
understand AS and
improve life
![Page 18: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/18.jpg)
https://www.angelmanclinicaltrials.com/drug-development
UConn/Ovid
![Page 19: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/19.jpg)
How can we restore UBE3A? Gene Therapy
Dr. Steve Gray, PhD
University of Texas,
Southwestern Medical
Center
• ASF funded the first studies of gene therapy back in 2005 and 2007.
• More recent study (2017) was a collaboration with Dr. Ben Philpot at
University of North Carolina and is being developed by AskBio.
• Approach is being pursued by PTC therapeutics, UPenn Orphan
Disease Center and potentially others.
![Page 20: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/20.jpg)
How much UBE3A is needed?
• Anjali Sadhwani and Wen-Hann Tan (Boston Children’s Hospital)
identified two families with a mutation that disrupts the short
“form” of UBE3A protein.
• The three kids in these families are less strongly affected—
individuals have speech and improved motor skills.
• Studies from Elgersma and Chamberlain labs suggest that these
individuals have ~12-18% of typical UBE3A levels.
![Page 21: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/21.jpg)
Is too much UBE3A bad?
• Kids with Dup15q syndrome have 1 or 2 extra copies of UBE3A.
• Early studies and genetics suggest that excess UBE3A is causing
many aspects of this disorder.
• Ben Philpot’s lab has made mice with extra copies of UBE3A to test
this in a mouse model.
• ASF collaborates closely-–and shares a research conference-–with
Dup15q Alliance.
![Page 22: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/22.jpg)
Every child with AS has an intact copy of UBE3A,
but it is silenced
Activation of paternal UBE3A is an attractive therapeutic strategy
MAGEL2
NDN
SNURF-
SNRPN
MKRN3
UBE3A
ATP10A
SNORD116
UBE3A-ATS
IPW
BP1
BP2
PWS-IC
PAT
MAT
AS-IC B
P3
• ASF funded a study in Ben Philpot’s lab (2009) that first showed
paternal UBE3A could be activated.
![Page 23: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/23.jpg)
UBE3A-ATSUBE3A
UBE3A-ATSUBE3A
UBE3A-ATS silences paternal UBE3A
MAGEL2
NDN
SNURF-
SNRPN
MKRN3
UBE3A
ATP10A
SNORD116
UBE3A-ATS
IPW
BP1
BP2
PWS-IC
PAT
MAT
AS-IC BP3
• ASF funded Dr. Art Beaudet (2011) to better understand how this
happens.
![Page 24: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/24.jpg)
Small molecule activators prevent the UBE3A-ATS
from being produced
• Topotecan was first example.
• ASF funded a recent study (2017) of additional small molecule
activators that work by an unknown mechanism.
• Licensed by Pinnacle Hill and being developed in collaboration with
Ben Philpot.
Topotecan
Dr. Ben Philpot, PhD
University of North Carolina
![Page 25: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/25.jpg)
UBE3A-ATSUBE3A
CRISPR strategy stops UBE3A-ATS
Dr. Mark Zylka, PhD
University of North Carolina
• CRISPR has a small RNA that guides a larger protein to a specific
spot on the DNA where it stops UBE3A-ATS.
• CRISPR does not need to cut the DNA = safer therapy.
• Can be delivered by AAV, even before birth, if necessary.
![Page 26: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/26.jpg)
5’
3’
5’
5’
3’
3’
5’
3’
UBE3A
UBE3A-ATS
ASOs
ASOs cut UBE3A-ATS, which derails the train
• ASF funded Art Beaudet to investigate this in mouse and Stormy
Chamberlain to investigate this in human neurons.
• This is how therapeutics being developed by Genetx, Roche, and
Ionis work.
![Page 27: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/27.jpg)
Other methods to cut UBE3A-ATS may also work
• Short hairpin RNAs (shRNAs) cut RNA in specific spots.
• shRNAs designed to cut UBE3A-ATS activate paternal UBE3A
• shRNAs can be delivered by AAV for one-and-done treatment
• Being developed by Ovid Therapeutics
1.0
1.3
1.0
0.7
1.0
0.6
1.0
2.2
0
0.5
1
1.5
2
2.5
Re
lati
ve
RN
A e
xp
ress
ion
SNORD116 SNORD115 ATS UBE3A
SCRAM shRNA UBE3A-ATS shRNA
Dr. Noelle Germain, PhD
UConn Health
Joseph Wagstaff Fellow
![Page 28: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/28.jpg)
Questions remaining about restoring UBE3A
• Which form of UBE3A is best for maximal benefit?
• What are expectations for recovery based on intervention
age?
• Do we need to target the whole brain or is one region
sufficient?
• What percentage of neurons must be infected?
• What are dangers of too much UBE3A, and how do we limit
chances of this?
![Page 29: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/29.jpg)
Enabling clinical trials
• ASF funded work on a mouse model that allows UBE3A to be
restored at different times during development to determine the
best time to restore for best therapeutic potential. (Elgersma)
• ASF funded work to study an EEG biomarker in AS mice and
humans with AS. Biomarkers allow us to determine whether
therapeutics are working. (Philpot and Hazlett)
![Page 30: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/30.jpg)
Which cells in the brain make/need UBE3A?
Dr. Ype Elgersma, PhD
Erasmus Medical Centre, Rotterdam
• Striatum is involved in motor learning, speech, emotional
regulation, and cognition.
• Does loss of UBE3A in the striatum cause many of the mouse
symptoms of AS?
• Important to understand the specific brain functions disrupted
by AS, so we know where therapeutics need to be delivered.
![Page 31: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/31.jpg)
Which cells in the brain make/need UBE3A?
• Already collected brain samples from hon-human primates
(Rhesus macaque) across different stages of life from embryo to
adulthood.
• Where is UBE3A found—brain regions and cell types?
• Important to understand where therapeutics need to reach
(biodistribution) to best treat AS.
Dr. Ben Philpot, PhD
University of North
Carolina
https://thebrain.mcgill.ca/
![Page 32: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/32.jpg)
Biomarkers of language in AS
• Need to identify biomarkers of language function in AS.
• Study will measure brain responses to different aspects of
language processing in AS.
• Important to identify objective ways to measure improvement in
language.
Dr. Charlotte DiStefano, PhD and Dr. Shafali Jeste, MD
UCLA Semel Institute for Neuroscience
![Page 33: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/33.jpg)
ASF’s research funding philosophy
Studies to better
understand UBE3A
High-risk, high-
reward studies to
find therapeutics
Clinical studies to
understand AS and
improve life
![Page 34: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/34.jpg)
Improving the quality of life for individuals with AS
Rotaru, Mientjes, and Elgersma, 2020
![Page 35: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/35.jpg)
Can we study language in AS mice?
Dr. R. Holly Fitch, PhD
University of Connecticut
• Determine the brain circuitry required for reduced communication
in AS mice—motor circuitry?
• Important to understand the brain region involved in
speech/language disorder in AS and the therapeutic window for
improving it.
![Page 36: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/36.jpg)
Approaches to improve communication in AS
Dr. H.A. Moll, MD
Erasmus Medical Centre,
Rotterdam
• High intensity versus low intensity training of parents and
caregivers to use/model AAC.
• Determine best ways to improve communication.
• Create a successful communication training program that families
can replicate at home.
Dr. Samuel Sennott, PhD
Portland State University
![Page 37: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/37.jpg)
Do individuals with AS have cortical visual impairment?
Dr. Karen Erickson, PhD
University of North Carolina
• Cortical visual impairment (CVI) is a type of vision impairment that
may affect balance, walking, communication, and behavior.
• Determine the prevalence and severity of CVI in AS.
• Determine whether CVI has an effect on communication in AS.
https://cvi.aphtech.org/
![Page 38: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/38.jpg)
Therapeutic development for neuron dysfunction
Dr. Kiyoshi Egawa, PhD
Hokkaido University
Graduate School of
Medicine, Japan
• AS neurons have deficits in the mechanisms that keep neurons
responsive to signals from other neurons –tonic inhibition.
• OV101, also called Gaboxadol, corrects this.
• Further studies to understand the brain regions and processes
impacted by this deficit
![Page 39: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/39.jpg)
Testing CBD in a mouse model to inform future clinical trials
Dr. Paul Carney, MD
University of North Carolina
• Cannabidiol (CBD) provides relief from seizures (and other?) for
some individuals with AS.
• CBD reduced seizure severity in mouse model, but at high doses
causes a mild sedative effect.
• Testing CBD carefully is important for determining parameters for
future clinical trials.
![Page 40: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/40.jpg)
15q Clinic Network provides an important research platform
![Page 41: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/41.jpg)
LADDER database links multiple sources of
clinical information for research
• Linking Angelman and Dup15q Data for Expanded Research
• Combines data from 15q Clinics Network, the Angelman Syndrome
Natural History Study, ASF and Dup15q Alliance registries, and the
Global Angelman Syndrome Registry
• Led by RTI International and supported by ASF, Dup15q Alliance,
and industry partners
![Page 42: Angelman Syndrome: Research Updates ASF Research Updates · Angelman Syndrome: Research Updates Ben Philpot, Ph.D. , University of North Carolina Stormy Chamberlain, Ph.D., University](https://reader033.fdocuments.in/reader033/viewer/2022042712/5f9bdec516af82051d219175/html5/thumbnails/42.jpg)
Our Research Goal
• To improve the lives of individuals with Angelman syndrome